

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

AACR 2026 PREVIEW: CSTONE TO PRESENT PRECLINICAL DATA FOR THREE PROPRIETARY PIPELINE ASSETS

This announcement is made by CStone Pharmaceuticals (the “Company,” together with its subsidiaries, collectively referred to as the “Group” or “CStone”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

.....

CStone today announced that preclinical data for three of its proprietary pipeline assets have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, one of the most influential scientific conferences globally in cancer research. The meeting will be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, United States. The related abstracts will be published in the AACR official journal Cancer Research on April 3, 2026.

Details of the accepted abstracts and poster presentation schedule are as follows:

CS5007—an EGFR/HER3 bispecific ADC

CS5007 is a potential best-in-class (BIC) antibody-drug conjugate (ADC) in precision oncology. By simultaneously targeting EGFR and HER3, the molecule is designed to address challenges associated with tumor heterogeneity. CS5007 is being developed for multiple solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and triple-negative breast cancer (TNBC).

- Abstract Title: Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload

- Presentation Type: Poster
- Location: Section 17, Board #11
- Date & Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM (PT)
- Poster Number: 1823

CS5008—an SSTR2/DLL3 bispecific ADC

CS5008 is a novel SSTR2/DLL3 bispecific ADC developed using CStone’s proprietary antibody and linker-payload technologies. By dual targeting SSTR2 and DLL3—two antigens frequently co-expressed in neuroendocrine neoplasms (NENs), small cell lung cancer (SCLC), and other malignancies—CS5008 is designed to address tumor heterogeneity inherent challenge to single-target therapies.

- Abstract Title: Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor payload for small cell lung cancer and neuroendocrine tumors
- Presentation Type: Poster
- Location: Section 17, Board #10
- Date & Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM (PT)
- Poster Number: 1822

CS5006—an ITGB4-targeting ADC

CS5006 is a potential first-in-class (FIC) ADC, targeting the novel antigen integrin $\beta 4$ (ITGB4). CStone identified elevated ITGB4 expression across multiple tumor types—including NSCLC, CRC, and SCCHN—with minimal expression observed in normal tissues. This profile indicates a wide therapeutic window and significant clinical potential.

- Abstract Title: Preclinical efficacy and safety of CS5006, a novel integrin $\beta 4$ -targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload
- Presentation Type: Poster
- Location: Section 17, Board #9
- Date & Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM (PT)
- Poster Number: 1821

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The Company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on

The Stock Exchange of Hong Kong Limited: THE COMPANY CANNOT GUARANTEE THAT WE MAY BE ABLE TO ULTIMATELY DEVELOP AND MARKET CS5006, CS5007 AND CS5008 SUCCESSFULLY. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, March 18, 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.